- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.04. | EXACT Therapeutics AS: EXACT Therapeutics - Annual Report 2025 | 16 | Oslo Børs | ||
| 26.03. | EXACT Therapeutics AS: Share capital increase registered | 1 | Oslo Børs | ||
| 13.03. | EXACT Therapeutics AS - Minutes from extraordinary general meeting on 13 March 2026 | - | Oslo Børs | ||
| EXACT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 03.03. | EXACT Therapeutics AS: EXACT Therapeutics - First patient dosed in Europe in Phase 2 trial in patients with locally advanced pancreatic cancer | 3 | Oslo Børs | ||
| 27.02. | EXACT Therapeutics AS: Notice of extraordinary general meeting | 2 | Oslo Børs | ||
| 27.02. | EXACT Therapeutics AS: Warrants exercise | - | Oslo Børs | ||
| 12.02. | EXACT Therapeutics AS: Financial calendar | - | Oslo Børs | ||
| 11.02. | EXACT Therapeutics AS: EXACT Therapeutics: Investor presentation for the global investor call regarding the ongoing warrants exercise program | 2 | Oslo Børs | ||
| 06.02. | EXACT Therapeutics AS: EXACT Therapeutics: Global investor call regarding the ongoing warrants exercise program | 1 | Oslo Børs | ||
| 05.02. | EXACT Therapeutics AS: EXACT Therapeutics: Correction of final warrants exercise date | 2 | Oslo Børs | ||
| 05.02. | EXACT Therapeutics AS: EXACT Therapeutics: Warrants exercise by leading shareholders and primary insiders | 2 | Oslo Børs | ||
| 05.02. | EXACT Therapeutics AS: EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB | 2 | Oslo Børs | ||
| 27.01. | EXACT Therapeutics AS: EXACT Therapeutics: Positive initial safety read-out from the Phase 2 ENACT trial in pancreatic cancer, triggering option to exercise warrants | 1 | Oslo Børs | ||
| 08.01. | EXACT Therapeutics AS: EXACT Therapeutics' Phase 2 trial in pancreatic cancer patients to be presented at the 2026 ASCO Gastrointestinal Cancers Symposium | - | Oslo Børs | ||
| 25.11.25 | EXACT Therapeutics AS: EXACT Therapeutics to present company update | 1 | Oslo Børs | ||
| 24.11.25 | EXACT Therapeutics AS: New option program and receipt of share options by primary insiders | 4 | Oslo Børs | ||
| 24.06.25 | Exact Therapeutics AS: EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer | 269 | GlobeNewswire (Europe) | OSLO, Norway, June 24, 2025 (GLOBE NEWSWIRE) -- EXACT Therapeutics (Euronext Growth: EXTX), a clinical-stage precision medicine company, is pleased to announce first patient dosed in its ENACT trial.... ► Artikel lesen | |
| 20.05.25 | Exact Therapeutics AS: EXACT Therapeutics announces positive final results in Phase 1 ACTIVATE trial in liver metastases from colorectal cancer | 392 | GlobeNewswire (Europe) | These results indicate that EXACT Therapeutics' Acoustic Cluster Therapy (ACT®) significantly enhances the local effect of chemotherapyIn the patients who had a response to chemotherapy, ACT-treated... ► Artikel lesen |
18 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 28,510 | -2,11 % | Qiagen: Von der Übertreibung direkt in eine Untertreibung gelaufen? | Am späten Montagabend legte Qiagen vorläufige Zahlen zum ersten Quartal vor, am gestrigen Dienstag fiel die Aktie daraufhin auf das tiefste Kursniveau seit Herbst 2019. Da die 2026er-Prognose gesenkt... ► Artikel lesen | |
| EVOTEC | 5,005 | -2,63 % | Evotec-Aktie mit +46% - kommt das Comeback? | Die Evotec-Aktie hat zuletzt kräftig zugelegt und stieg um rund +46% an. Damit hat sich das Chartbild deutlich verbessert und eine mögliche Trendwende rückt in den Fokus. Nach der dynamischen Rallye... ► Artikel lesen | |
| ERASCA | 9,265 | -6,32 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| BIONTECH | 86,20 | -1,09 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| STRUCTURE THERAPEUTICS | 41,360 | -4,94 % | Here is Why Structure Therapeutics (GPCR) is One of the Top Biotech Names to Look at | ||
| BEAM THERAPEUTICS | 29,345 | -3,98 % | Beam Therapeutics (BEAM) Reveals Encouraging Results From Risto-Cel Phase 1/2 BEACON Study | ||
| TANGO THERAPEUTICS | 23,410 | -6,84 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| COGENT BIOSCIENCES | 35,520 | -2,31 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST) | Bezuclastinib NDA submitted under the FDA's RTOR program based on positive results from Phase 3 PEAK trial; bezuclastinib previously granted Breakthrough Therapy Designation in GISTBezuclastinib combination... ► Artikel lesen | |
| DESIGN THERAPEUTICS | 16,450 | +28,42 % | Design Therapeutics, Inc.: Design Therapeutics Announces First Quarter 2026 Financial Results and Recent Business Updates | Additional Detail Provided for RESTORE-FA (DT-216P2) Trial Design, Dosing and Endpoints David Shapiro, M.D., Appointed to Board of Directors, Strengthening Clinical and Regulatory Expertise Cash and... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 52,76 | -2,02 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST- (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $930 - $945 million -- KPL-387... ► Artikel lesen | |
| ADMA BIOLOGICS | 10,565 | -2,98 % | Summers Value Fund adds TBPH, exits ADMA among Q1 moves | ||
| SUMMIT THERAPEUTICS | 20,840 | -1,98 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| MODERNA | 39,135 | -2,76 % | Moderna, Inc.: Moderna Announces Initiation of Phase 3 Study of Investigational mRNA Pandemic Influenza Vaccine Candidate | Phase 3 study is supported by the Coalition for Epidemic Preparedness Innovations to help strengthen global preparedness against a significant pandemic threat CAMBRIDGE, MA / ACCESS Newswire / April... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 22,460 | -3,56 % | Arcutis Biotherapeutics, Inc.: Arcutis' ZORYVE (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines | Strong recommendation with high certainty of clinical evidence underscores proven efficacy, safety, and tolerability of ZORYVE cream as a steroid-free topical phosphodiesterase type 4 (PDE4) inhibitorAtopic... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,24 | -4,72 % | Apogee Therapeutics Inc. (APGE): Primary Challenger to Established Blockbusters |
EXACT THERAPEUTICS AS gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,095 Euro und damit +4,40 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXACT THERAPEUTICS AS finden Sie auf Wallstreet Online.